News & Webinars

News and Content

The Latest News from Agilex Biolabs

Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical laboratory for clinical trials is showcasing its new $1.5m vaccine and immunobiology laboratory at BIO Asia Taiwan 2021. The facility, the most sophisticated in APAC, is designed for biotechs and pharma from around the world for advanced clinical research including RNA vaccines, siRNA/miRNA clinical targets and gene therapy studies.

Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical laboratory for clinical trials today announced that the Premier of South Australia the Hon Steven Marshall MP has launched its new $1.5m vaccine and immuno-biology laboratory. The facility, the most sophisticated in APAC, will attract biotechs and pharma from around the world for advanced clinical research.

Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials announced for BIO Korea 2021 that their upgraded and expanded biolabs at the Australian headquarters is now complete.

The labs have been expanded by 30% to cater for increased demand for bioanalysis and biomarkers in clinical studies from clinical stage biotechs.
Inflammation is a complex biological process involving a host of resident and recruited immune cells which are mobilized to infiltrate tissues in response to invading pathogens. These immune cells boast elevated numbers and heightened activation as they churn out inflammatory mediators, which act in unison to coordinate and modulate the immune response.

Choosing the right bioanalytical platform for your immunology clinical trial is critical to data collection. But navigating the intricate inflammation process can be difficult. What do these platforms look like in use, and how should you go about selecting the right one?
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, said biotechs with first-in-human studies can leverage significant quality, speed and cost advantages working with their company TetraQ toxicology for pre-clinical research in Australia.

TetraQ is a NATA-accredited, GLP-recognised rodent toxicology facility.
This webinar examines the hot topics in immunoassay bioanalysis for biotechs navigating the immunogenicity and biomarker requirements for clinical trials. Join the discussion with panelists from Agliex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, and B2S Life Sciences, a biotherapeutic enablement company advancing improved analytical methods and outcomes for developers of biotherapeutic drugs and diagnostics
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced the purchase of leading biolab TetraQ, based out of the University of Queensland.

Agilex Biolabs CEO Jason Valentine said the Board and senior management at Agilex Biolabs were extremely pleased with the purchase of such a high-calibre bioanalytics company.

“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said.
Agilex Biolabs is the leading bioanalytical laboratory in Asia-Pacific with the most advanced platforms for sensitive technologies. They include Sciex API 6500+ LC-MS/MS, Sciex API 4000 LC-MS/MS systems; Gyrolab™ Xplore, Luminex MAGPIX xPONENT ™, MSD Quickplex 120 and BD FACSymphony™ A3 20 colour flow cytometry analysers, so we have the capability to deliver any sized project.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.
Why Australia is the World’s Leading Early Phase Destination – Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs Increasingly Sponsors are wanting to be actively involved in the core clinical partner selection because they matter to the success of their clinical research.
Hi, everyone. I'm Arsalan Arif, the publisher of Endpoints News, and I'm pleased to be your moderator today. Today's webinar is sponsored by Agilex Biolabs in Australia. Our topic is Why Australia is the World's Leading Early Phase Destination - Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs. I'm joined by two great guests today. Kurt Sales, the Director of Immunoassay at Agilex Biolabs, and Jane Kelly, the CEO of CMAX Clinical Research.
Gathering together the key clinical service providers for a trial can be a daunting process – especially if you are going off-shore to reactivate trials or start new trials to make up for COVID delays.

However, Australia offers a refreshingly streamlined process because of its group of proven top-tier providers that regularly work together so are fully engaged and in sync with processes and each other’s requirements and capabilities. This makes setting up trials in Australia a smooth, professional, and rapid process for biotechs. This webinar looks at how moving trials to Australia could be much easier than you think.
All right. Hi everybody. I’m Arsalan Arif, the publisher of Endpoints News and I’m pleased to be your moderator today. Today’s webinar is sponsored by Agilex Biolabs in Australia and our topic is the Australian Advantage, de-risk your early phase trials. I’m joined by Dr Kurt Sales today with Agilex Biolabs. He’s got an approximately 20 minute presentation and we’re going to follow it up with a quick Q&A. And now I give you Dr Kurt Sales.